Unfair Advantages for Hepatocellular Carcinoma Patients Listed for Liver Transplant in Short‐Wait Regions Following 2015 Hepatocellular Carcinoma Policy Change

Max N. Brondfield, Jennifer L. Dodge, Ryutaro Hirose, Julie Heimbach, Francis Y. Yao, Neil Mehta – 13 December 2019 – For patients with hepatocellular carcinoma (HCC) listed for liver transplantation (LT), United Network for Organ Sharing (UNOS) enacted policy changes in 2015 to improve equity between HCC and non‐HCC patients. We evaluated the impact of these changes on regional disparities in wait‐list dropout and LT.

Reply

Marie Sinclair, Brooke Chapman, Rudolf Hoermann, Peter W. Angus, Adam Testro, Thomas Scodellaro, Paul J. Gow – 13 December 2019

LiverLearning®: 2019 Webinar: Cannabis and the Liver: Update for the Hepatologist

Use of cannabis is growing in the population with increased interest in potential medicinal use as well as recreational use depending on the jurisdiction. Given this, clinicians need to have an understanding about cannabis and its potential impacts on liver disease. This webinar will provide attendees information about cannabis, its major components (THC/CBD) as well as discuss potential policy implications regarding transplantation.

Splicing Regulator p54nrb/Non–POU Domain–Containing Octamer‐Binding Protein Enhances Carcinogenesis Through Oncogenic Isoform Switch of MYC Box–Dependent Interacting Protein 1 in Hepatocellular Carcinoma

Zhixiang Hu, Liangqing Dong, Shengli Li, Zhe Li, Yejun Qiao, Yuchen Li, Jie Ding, Zhiao Chen, Yangjun Wu, Zhen Wang, Shenglin Huang, Qiang Gao, Yingjun Zhao, Xianghuo He – 9 December 2019

Hepatitis C Guidance 2019 Update: American Association for the Study of Liver Diseases–Infectious Diseases Society of America Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection

Hepatitis C Guidance 2019 Update: American Association for the Study of Liver Diseases–Infectious Diseases Society of America Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection

Magnetic Resonance Cholangiopancreatography Severity Predicts Disease Outcomes in Pediatric Primary Sclerosing Cholangitis: A Reliability and Validity Study

Kedar Patil, Amanda Ricciuto, Alaa Alsharief, Jehan Al‐Rayahi, Afsaneh Amirabadi, Peter C. Church, Binita M. Kamath, Mary‐Louise C. Greer – 6 December 2019 – Magnetic resonance cholangiopancreatography (MRCP) has not been assessed as a surrogate biomarker in pediatrics. We aimed to determine the inter‐rater reliability, prognostic utility, and construct validity of the modified Majoie endoscopic retrograde cholangiopancreatography classification applied to MRCP in a pediatric primary sclerosing cholangitis (PSC) cohort.

Subscribe to